



Citation for published version:

Freeman, TP, Wilson, J & Mackie, C 2018, 'Commentary on Salloum et al. (2018): Rethinking adolescent cannabis use and risk perception', *Addiction*, vol. 113, no. 6, pp. 1086-1087. <https://doi.org/10.1111/add.14212>

DOI:

[10.1111/add.14212](https://doi.org/10.1111/add.14212)

Publication date:

2018

Document Version

Peer reviewed version

[Link to publication](#)

This is the peer reviewed version of the following article: Freeman, TP, Wilson, J & Mackie, C 2018, 'Commentary on Salloum et al. (2018): Rethinking adolescent cannabis use and risk perception' *Addiction*, vol. 113, no. 6, pp. 1086-1087, which has been published in final form at: <https://doi.org/10.1111/add.14212>. This article may be used for non-commercial purposes in accordance with Wiley Terms and conditions for Self-Archiving.

University of Bath

General rights

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Commentary on Salloum et al.(2018): rethinking adolescent cannabis use and risk perception

Tom P Freeman^{1,2}, Jack Wilson¹, Clare Mackie¹

¹National Addiction Centre, Institute of Psychiatry, Psychology & Neuroscience, King's College London, UK

²Clinical Psychopharmacology Unit, University College London, UK

TF was funded by a Senior Academic Fellowship from the Society for the Study of Addiction. JW was funded by the Parents and Carers' Leave Fund at King's College London awarded to CM. No financial or other relevant links to companies with an interest in the topic of this article.

With rapidly evolving cannabis markets in the USA and elsewhere, collecting data on different cannabis products and routes of administration will be important for understanding new trends in adolescent cannabis use and risk perception

The Monitoring the Future (MTF) survey from 1975-present has documented a compelling negative correlation, between changes in the perceived risks of cannabis and prevalence of cannabis use in adolescents. Under the assumption that these variables are causally related, they are typically interpreted as evidence that changes in risk perception influence subsequent cannabis use (1). This scenario offers a major argument against the legalisation of cannabis, as increased societal acceptance of cannabis may decrease adolescents' perception of risks and therefore increase use. Less attention has been paid to an alternative interpretation, that using cannabis may decrease the perceived risks of cannabis. In a longitudinal study of 9,929 adolescents from the MTF survey, Salloum et al. (2) provide evidence to support both interpretations. Crucially, associations between cannabis use and risk perception were over two times stronger than those between risk perception and cannabis use.

These findings challenge the assumption that the relationship between risk perception and cannabis use will always be unidirectional. Additional factors may also contribute to the interplay between cannabis use and risk perception. Cannabis products with high delta-9-tetrahydrocannabinol (THC) concentrations are rated by users as carrying greater risks (3) and are associated with poorer mental health and addiction outcomes (3-6). Ultra-high potency extracts (~70% THC) currently form over 20% of the market in Washington State (7) and will be assessed in the new Adolescent Brain and Cognitive Development cohort (8). As cannabis markets in the USA continue to evolve, collecting data on different cannabis products in future iterations of the MTF survey could improve our understanding of risk perception and its relationship to patterns of use.

Additionally, the risks of using cannabis may be influenced by route of administration (e.g. smoked, vaporized or eaten; (9-11)). In 2017 MTF began collecting data on cannabis vaping for the first time; over a quarter of cannabis-using respondents had experience of vaping cannabis (12). Although research into cannabis vaping is in its infancy, it does raise parallel issues to those of e-cigarettes and smoked tobacco (13) where comparative assessment of risk is of paramount importance for public health (14).

Adolescents' decisions to use cannabis are unlikely to be driven by risk alone; perceived benefits may also be important. An international survey of 5,791 drug users (15) found that cannabis was rated as having the highest beneficial effects of all 15 drugs included, as well as the greatest benefit-to-harm ratio. Moreover, positive experiences of using cannabis in adolescence are associated with a greater incidence of cannabis dependence in early adulthood (16). Understanding the competing roles of perceived benefits and risks could improve our understanding of trends in adolescent cannabis use, in addition to associations between risk and use reported by Salloum et al.(2).

The results of Salloum et al. have direct implications for the development of programs designed to prevent or delay the onset of cannabis use in adolescents. Current evidence-based programs often include components that are designed to address adolescents' perceptions of the harmful effects of drugs (17) which are shown to be successful in deterring the onset of cannabis and its progression of use (18). For prevention to be most effective it needs to be introduced during the early adolescent years, prior to the initial exposure of cannabis use and before the effects of cannabis can impact on an individual's perception of risk. In this way an individual's risk perception can be guided by scientific evidence on objective risks, rather than the immediate subjective effects of the drug. In order to be relevant for the next generation of young people, drug prevention programs should include up-to-date information on the risks associated with new cannabis products and routes of administration.

1. VOLKOW, N. D., BALER, R. D., COMPTON, W. M. & WEISS, S. R. (2014) Adverse health effects of marijuana use, *New England Journal of Medicine*, 370, 2219-2227.
2. SALLOUM, N. C., KRAUSS, M. J., AGRAWAL, A., BIERUT, L. J. & GRUCZA, R. A. (2018) A reciprocal effects analysis of cannabis use and perceptions of risk, *Addiction*, doi: 10.1111/add.14174.
3. FREEMAN, T. & WINSTOCK, A. (2015) Examining the profile of high-potency cannabis and its association with severity of cannabis dependence, *Psychological medicine*, 45, 3181-3189.
4. DI FORTI, M., MARCONI, A., CARRA, E. et al. (2015) Proportion of patients in south London with first-episode psychosis attributable to use of high potency cannabis: a case-control study, *The Lancet Psychiatry*, 2, 233-238.
5. MEIER, M. H. (2017) Associations between butane hash oil use and cannabis-related problems, *Drug & Alcohol Dependence*, 179, 25-31.
6. FREEMAN, T. P., VAN DER POL, P., KUIJPERS, W. et al. (2018) Changes in cannabis potency and first-time admissions to drug treatment: a 16-year study in the Netherlands, *Psychological medicine*, doi: 10.1017/S0033291717003877.
7. SMART, R., CAULKINS, J. P., KILMER, B., DAVENPORT, S. & MIDGETTE, G. (2017) Variation in cannabis potency and prices in a newly-legal market: Evidence from 30 million cannabis sales in Washington State, *Addiction*, 112, 2167-2177.
8. LISDAHL, K. M., SHER, K. J., CONWAY, K. P. et al. (2018) Adolescent brain cognitive development (ABCD) study: Overview of substance use assessment methods, *Developmental Cognitive Neuroscience*, <https://doi.org/10.1016/j.dcn.2018.02.007>.
9. NEWMAYER, M. N., SWORTWOOD, M. J., ABULSEUD, O. A. & HUESTIS, M. A. (2017) Subjective and physiological effects, and expired carbon monoxide concentrations in frequent and occasional cannabis smokers following smoked, vaporized, and oral cannabis administration, *Drug & Alcohol Dependence*, 175, 67-76.
10. HINDOCHA, C., FREEMAN, T. P., FERRIS, J. A., LYNKEY, M. T. & WINSTOCK, A. R. (2016) No smoke without tobacco: a global overview of cannabis and tobacco routes of administration and their association with intention to quit, *Frontiers in psychiatry*, 7, 104.
11. EARLEYWINE, M. & BARNWELL, S. S. (2007) Decreased respiratory symptoms in cannabis users who vaporize, *Harm Reduction Journal*, 4, 11.
12. JOHNSTON, L. D., MIECH, R. A., O'MALLEY, P. M. et al. (2018) Monitoring the Future national survey results on drug use: 1975-2017: Overview, key findings on adolescent drug use (The University of Michigan, Ann Arbor: Institute for Social Research).
13. BUDNEY, A. J., SARGENT, J. D. & LEE, D. C. (2015) Vaping cannabis (marijuana): Parallel concerns to e-cigs?, *Addiction*, 110, 1699-1704.
14. MCNEILL, A., BROSE, L. S., CALDER, R., BAULD, L. & ROBSON, D. (2018) Evidence review of e-cigarettes and heated tobacco products 2018. A report commissioned by Public Health England (London, Public Health England).
15. MORGAN, C. J., NORONHA, L. A., MUETZELFELDT, M., FEILDING, A. & CURRAN, H. V. (2013) Harms and benefits associated with psychoactive drugs: findings of an international survey of active drug users, *Journal of Psychopharmacology*, 27, 497-506.
16. FERGUSSON, D. M., HORWOOD, L. J., LYNKEY, M. T. & MADDEN, P. A. (2003) Early reactions to cannabis predict later dependence, *Archives of general psychiatry*, 60, 1033-1039.
17. EISEN, M., ZELLMAN, G. L., A., M. H. & M., M. D. (2002) Evaluating the Lions-Quest "Skills for Adolescence" drug education program: first year behaviour outcomes, *Addictive Behaviors*, 619-32.
18. FAGGIANO, F., MINOZZI, S., VERSINO, E. & BUSCEMI, D. (2014) Universal school-based prevention for illicit drug use, *The Cochrane Library*.